Blood Markers to Track Treatment in Metastatic Pancreatic Cancer
Studies blood small molecules called miRNAs to see if they track pancreatic cancer treatment response.
Plain-language title generated from the registry record
Registry title: Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)
Key facts
- Where
- São Paulo, BrazilSee the site
Where in Brazil
- A Beneficência Portuguesa de São PauloSão Paulo, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Benedito Mauro Rossi
- Trial code
- NCT06945978
- Record updated
- 27 April 2025
- Original description
This study is being conducted to better understand how pancreatic cancer behaves during treatment and how we can improve methods for monitoring disease progression. The research aims to determine whether small molecules present in the blood, called miRNAs, can help doctors assess whether the treatment is working or needs adjustment. With this, we hope to make cancer monitoring less invasive and more precise, allowing patients to receive more personalized and effective treatments.Read full original descriptionShow less
Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer
This study is being conducted to better understand how pancreatic cancer behaves during treatment and how we can improve methods for monitoring disease progression. The research aims to determine whether small molecules present in the blood, called miRNAs, can help doctors assess whether the treatment is working or needs adjustment. With this, we hope to make cancer monitoring less invasive and more precise, allowing patients to receive more personalized and effective treatments.
Inclusion: Patients diagnosed with metastatic PDAC; Patients who will start treatment with FOLFIRINOX; 18 years or older; Who agree to participate in the study by signing the Informed Consent Form.
Exclusion: Patients who have previously undergone chemotherapy, whether neoadjuvant, adjuvant, or any prior first-line treatment; Patients who do not meet the minimum criteria to receive the proposed regimen, such as those with hyperbilirubinemia, those who are not candidates due to age or performance status deterioration.